Clin2
NCT07324837Worth exploringRecruiting

Study of a clot-busting drug for stroke up to 24 hours later

Ischemic Stroke, Acute

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
990 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older.
  • Your stroke started between 4.5 and 24 hours ago (or you last felt normal in that time).
  • You had little or no disability before the stroke (able to do daily tasks).
  • A brain scan shows a blockage in a large artery and that the area at risk is bigger than the area already damaged.
  • Your stroke symptoms are moderate to moderately severe (score of 6 to 25 on a stroke scale).
  • You are not scheduled for or cannot have a clot-removal procedure or standard clot-busting medicine.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT05697575Recruiting
Staphylokinase during stroke blood-flow treatment

This trial studies using a medication called non-immunogenic staphylokinase as part of standard clot-busting treatment for an acute ischemic stroke. It may help clinicians improve blood flow after the stroke using an approach designed to be less likely to trigger immune reactions.

Saint Petersburg
NCT07201688Recruiting· Phase 3
Extending the window for stroke clot-busting drug

This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.

Puyang, Henan
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires
NCT07375953Recruiting· Phase 2
Repeated clot-busting drug for stroke within 3 hours

This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.

Shenyang, None Selected
NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing

Hear when a new Ischemic Stroke, Acute trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.